WARREN, NJ, Dec. 17, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (Tevogen or Tevogen Bio Holdings Inc.) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics in the treatment of infectious disease and cancers, announced today that it will host an engaging panel discussion, Pioneering the Economics of Health: Balancing Access and Outcomes, during the 43rd Annual JP Morgan Healthcare Conference.

This panel will bring together global thought leaders to examine the critical interdependencies of the healthcare ecosystem, a dynamic interplay between patient access, medical innovation, payment mechanisms and health policy that is often overlooked when considering only one silo of it. The discussion will focus on:

• The challenges and opportunities presented by US leadership in health care innovation, particularly in balancing rising costs and delivering value.
• The impact of cost containment measures, including the Inflation Reduction Act, on drug development and patient access.
• The implications of the new US health care administration’s approach for global markets and the business model of the medical innovation industry.

The panelists consisted of Senior Partner at Simon-Kucher; Former Acting Under Secretary for Health, Department of Veterans Affairs and Former Commissioner, New Jersey Department of Health; Principal, Rubix Health, and Senior Fellow, Tufts Center for Evaluation of Value and Risk in Health and Venture Mentor, Johns Hopkins Tech Ventures, Former CMS Chief Clinical Officer and Director of The Office of Clinical Standards; Managing Director for Risk Advisory Services, Veritas; CEO of Tevogen Bio; CIO and Head of AI at Tevogen Bio.

Event Details

Date:
Monday, January 13, 2025

Location:
Marines’ Memorial Club & Hotel 609 Sutter St, San Francisco, CA 94102, United States

Time (PST):
3:15 PM “ 4:00 PM “ Pioneering Health Economics: Balancing Access and Outcomes
4:00 PM “ 6:00 PM “ Reception and Cocktails

For questions about additional event details, please contact [email protected].

About Tevogen Bio

Tevogen is a clinical-stage specialty immunotherapy company that uses one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment in infectious diseases, cancer, and neurological disorders, aiming to address the significant unmet needs of the large patient population. Tevogen Leadership believes that sustainability and commercial success in today’s healthcare era relies on ensuring patient access through advanced science and innovative business models. Tevogen has reported positive safety data from proof-of-concept clinical trials, and its key intellectual property assets are fully owned by the company, not subject to any third party licensing agreement. These assets include three granted patents, nine pending in the US and twelve ex-US pending patents, two of which are related to artificial intelligence.

Tevogen is driven by a team of highly experienced industry leaders and renowned scientists with global drug development and product launch experience. Tevogen’s leadership believes that accessible personalized therapies are the next frontier in medicine, and that disruptive business models are necessary to sustain medical innovation.

Contacts

Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
[email protected]

Source: Tevogen Bio Inc